Filing Flows › NovoCure (NVCR) › Guidance history
NovoCure (NVCR) guidance history: what it guided and what it reported
NovoCure gave guidance in 3 earnings releases on file since Apr 30, 2026. Its releases raised guidance once and lowered it 0 times.
Revenue
Every guided period is still to be reported.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | $690M–$710M (Apr 30, 2026) → raised $710M–$725M (Jul 23, 2026) → raised $736M–$743M (Oct 29, 2026) | — | to be reported | — |
Adjusted EBITDA
Every guided period is still to be reported.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | −$15.0M–$0 (Apr 30, 2026) → raised $0–$15.0M (Jul 23, 2026) → raised $24.0M–$34.0M (Oct 29, 2026) | — | to be reported | — |
The latest quarter
NovoCure, Q3 2026: revenue $193M (+16% year over year), operating margin -3.2%, net loss $10.4M, operating cash flow $22.7M. The chart follows the revenue to costs, profit and cash.
Questions
Does NovoCure beat its guidance?
NovoCure gave guidance in 3 earnings releases on file since Apr 30, 2026. Its releases raised guidance once and lowered it 0 times.
How often does NovoCure raise guidance?
Its earnings releases raised guidance once and lowered it 0 times since Apr 30, 2026.
Each guided period is held to the last guidance given before its figures were reported; a single figure counts as in line within 1% (0.25 pts for a rate). Reported figures are GAAP, from the company's filings; adjusted guidance shows its moves only.